Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2021-11-30 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
LYNPARZA GRANTED FDA PRIORITY REVIEW FOR OLYMPIA
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, which is a report of a foreign issuer pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934. It contains an announcement about the FDA granting Priority Review for Lynparza for a specific indication in breast cancer. The document is an SEC regulatory filing used by foreign companies to report material information between annual reports. It is not a full annual report, earnings release, or detailed financial report. The content is primarily a regulatory announcement about a drug development milestone and regulatory status update. Therefore, the document fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-11-30 English
Lynparza granted FDA Priority Review for OlympiA
Regulatory Filings Classification · 100% confidence The document is a press release issued via RNS (RNS Number : 0051U) on November 30, 2021, announcing that the supplemental New Drug Application (sNDA) for Lynparza has been accepted and granted Priority Review by the US FDA. This is a specific corporate event announcement regarding regulatory progress, not a comprehensive annual report (10-K), an interim report (IR), or a general earnings release (ER). It is a regulatory update concerning a specific drug application status. Since it is a formal announcement distributed through a regulatory news service (RNS) detailing a specific regulatory event (FDA Priority Review acceptance), it fits best under the general 'Regulatory Filings' category (RNS) as it is not covered by more specific codes like DIV, CAP, or MANG. Although it contains detailed medical/scientific information, its primary function here is the announcement of the regulatory action itself.
2021-11-30 English
DIRECTOR/PDMR SHAREHOLDING
Director's Dealing Classification · 100% confidence The document is a Form 6-K filed by AstraZeneca PLC, reporting a transaction involving shares held by a director (Chief Financial Officer) related to vesting of restricted stock units. The content focuses on a director's shareholding transaction, including details of the transaction, price, volume, and regulatory compliance with the EU Market Abuse Regulation. There is no financial performance data, earnings information, or management discussion. The document is a notification of a personal share transaction by a company director, which fits the definition of Director's Dealing filings.
2021-11-15 English
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is identified by the 'RNS Number : 4334S' header and explicitly mentions 'This information is provided by RNS, the news service of the London Stock Exchange.' The content details a 'Transaction by Person Discharging Managerial Responsibilities' (Dr Aradhana Sarin, CFO) regarding the vesting of American Depositary Shares (ADSs) and subsequent tax obligations. This type of insider transaction reporting, especially when filed via RNS, falls under the category of Director's Dealing (DIRS). Although it is an RNS announcement, the specific nature of the transaction (insider trade/vesting) makes DIRS a more precise classification than the general RNS fallback.
2021-11-15 English
AZN: YEAR TO DATE AND Q3 2021 RESULTS
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filed with the SEC by AstraZeneca PLC, reporting year-to-date and Q3 2021 financial results. It includes detailed financial data such as revenue, earnings per share, segment performance, and guidance. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year (Q3 2021) indicates this is an interim or quarterly report. The document is lengthy (15,000 characters) and contains substantive financial data, not merely an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2021-11-12 English
AZN: Year to date and Q3 2021 results
Earnings Release Classification · 100% confidence The document is an official 'Year to date and Q3 2021 results' announcement from AstraZeneca PLC. It contains detailed financial performance metrics, revenue breakdowns, EPS summaries, and management commentary regarding the fiscal period. It is not a full annual report (10-K) nor a mere announcement of a report (RPA), but rather the primary release of quarterly financial results. Therefore, it is classified as an Earnings Release (ER). 9M 2021
2021-11-12 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.